Hypertension and hyperlipidemia are common and powerful risk factors for cardiovascular disease. Although they may coexist in the same individual by chance, the syndrome of insulin resistance is the common mechanism in many individuals, in whom there is a specific lipoprotein profile of small, dense, low-density lipoprotein particles, reduced plasma high-density lipoprotein cholesterol levels, and increased plasma triglycerides. This lipoprotein profile may be exacerbated by diuretics or ␤-blockers. E pidemiologic studies have confirmed the independent prognostic significance of hypertension and elevated plasma total and lowdensity lipoprotein (LDL) cholesterol for the development of myocardial infarction or cardiac death.
pidemiologic studies have confirmed the independent prognostic significance of hypertension and elevated plasma total and lowdensity lipoprotein (LDL) cholesterol for the development of myocardial infarction or cardiac death. 1 Risk prediction and equations derived from studies such as this indicate that the risks associated with hypertension and hyperlipidemia are multiplicative. As a result, strategies for reducing the risk of myocardial infarction or stroke are based on the concept of multiple risk factor intervention 2 ; on the assumption that where hypertension and hyperlipidemia coexist, this is essentially a chance occurrence due to the high prevalence of both conditions in the community.
Recent evidence, however, suggests that there are specific associations between hypertension and dyslipidemia in a substantial proportion of hypertensive subjects. 3 As a group, patients with hypertension have more pronounced plasma glucose and insulin responses to an oral glucose challenge than do matched normotensive subjects, a metabolic abnormality that is not corrected by pharmacologic reduction of blood pressure. The higher plasma concentrations of insulin in hypertension result from the resistance of peripheral tissue to the action of insulin to stimulate glucose uptake, and may be found both in obese and nonobese patients. The characteristic lipoprotein profile in these patients is an increased plasma triglyceride concentration, reduced concentrations of high-density lipoprotein (HDL) cholesterol, and the presence of smaller, denser LDL particles than in normal subjects. Normotensive first-degree relatives of patients with hypertension also have insulin resistance and dyslipidemia, 4 but patients with secondary forms of hypertension do not. Although there is a genetic association between hypertension and insulin resistance, there is an additional environmental association in that insulin resistance and hyperinsulinemia 4 are more severe and more closely associated with hypertension in obese patients than in nonobese patients. 3 It has been proposed that this association is mediated through sympathetic overactivity, because both plasma insulin concentration and urinary norepinephrine exertion are significantly correlated with blood pressure. Intake of saturated fat is directly related to fasting and plasma insulin concentrations measured after stimulation with glucose, suggesting that dietary factors are also involved in the pathogenesis of insulin resistance. Nonpharmacologic interventions such as calorie restriction, weight loss, and exercise, all of which decrease insulin resistance, reduce sympathetic nervous system activity and blood pressure in parallel. 5 
EFFECT OF ANTIHYPERTENSIVE THERAPY ON LIPOPROTEIN PROFILE
Hypertension and dyslipidemia are major risk factors for the development of stroke or clinical coronary heart disease. Randomized clinical trials have demonstrated a more substantial effect on antihypertensive therapy on reducing the risk of stroke, compared with myocardial infarction. 6 Although many possible explanations have been offered for this discrepancy, one possibility is that the changes in glucose, insulin, and lipoprotein metabolism associated with hypertension may be exacerbated by the hypotensive agents used in most previous clinical studies, particularly diuretics and ␤-adrenergic antagonists. 7 The changes in the lipoprotein profile produced by the commonly used classes of antihypertensive agents are listed in Table 1 . Diuretics and ␤-adrenergic blockers cause a worsening in the lipoprotein profile that may be atherogenic, and may offset in part their beneficial effect on blood pressure. This adverse effect is mediated through an increase in insulin resistance. 3 It should be emphasized, however, that the adverse metabolic effects of antihypertensive agents listed in Table 1 have been demonstrated in short-term studies, often with high doses of the drug in question. Their relevance, if any, to the long-term risk of myocardial infarction or coronary death is unknown, and must be established by prospective randomized trials comparing drugs with equivalent antihypertensive effects but different metabolic profiles (see below).
RESPONSES TO LIPID-LOWERING AGENTS
The existence of a specific atherogenic lipoprotein profile associated with hypertension and insulin resistance raises the question of whether there may be different responses to lipid-lowering agents in normotensive and hypotensive subjects.
The most common lipid-lowering drugs currently in clinical use are the fibrates and HMG Co-A-reductase inhibitors (statins), whose effects on lipoprotein analyses in two major primary prevention trials 8, 9 are illustrated in Table 2 . A subgroup analysis of the Helsinki Heart Study argued that the beneficial effects of gemfibrozil in this trial were found exclusively in patients with the atherogenic lipoprotein profile (high triglyceride, low HDL cholesterol, small dense LDL particles), as opposed to those with isolated elevation of LDL cholesterol.
Although theoretical arguments might favor the use of fibrates in hypertensive patients with dyslipidemia, the subgroup analysis of the recently published Cholesterol and Recurrent Events trial 10 indicated equal benefit from lipid lowering with pravastatin in individuals with and without a history of hypertension. Abbreviations as in Table 1 .
AJH-JULY 1998 -VOL. 11, NO. 7 A more complete understanding of the effects of lipid reduction in hypertensive patients and of the influence of changes in lipid profiles as a result of antihypertensive therapy must await the completion of the Anti-Hypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), which is currently underway in the United States (Table 3) .
